PreCheck's Type V Facility DMF Is Not a PAI, and a CDMO Seat Does Not Transfer CGMP

When biopharmaceutical sponsors evaluate domestic contract development and manufacturing organizations (CDMOs) or plan capital expenditures for newly built U.S. drug substance and finished dosage form facilities, regulatory marketing claims frequently outpace administrative reality. Following the launch of the Food and Drug Administration's PreCheck Pilot Program and the agency's June 29, 2026 cohort announcement, commercial business development decks have begun spotlighting PreCheck participation as a commercial differentiator. CDMO presentations suggest that holding a seat in the pilot, submitting a Type V facility Drug Master File (DMF), and completing an FDA Pre-Operational Review (POR) site visit effectively "pre-clears" the facility, minimizes regulatory inspection risk, or relieves the sponsor of primary oversight burdens.

For Chemistry, Manufacturing, and Controls (CMC) executives, quality directors, and regulatory affairs teams preparing commercial Requests for Quotation (RFQs), these assertions introduce severe operational and compliance risks.

A sponsor is issuing an RFQ for a newly constructed U.S. sterile fill-finish or API facility, or negotiating commercial terms with a CDMO selected for the FDA PreCheck Pilot Program. The CDMO states that because it has been selected by FDA, will maintain an actively assessed Type V facility DMF, and will host a Pre-Operational Review site visit, the sponsor can treat the facility as pre-approved, anticipate an exemption or abbreviated scope for the product-specific Pre-Approval Inspection (PAI), and rely on the CDMO's PreCheck status to satisfy current Good Manufacturing Practice (CGMP) obligations under 21 CFR Part 211. Can the sponsor accept these assertions in its regulatory filing and quality agreement?

The direct regulatory answer is no. FDA PreCheck Phase 1, a Type V facility DMF, and a Pre-Operational Review site visit do not replace a Pre-Approval Inspection under Compliance Program 7346.832, do not approve or license a manufacturing facility, and do not permit an application holder to transfer its statutory CGMP responsibilities under 21 CFR Part 211 to a contract facility:

1. PreCheck is voluntary and does not guarantee regulatory shortcuts. Under FDA's program FAQ, participation is voluntary and is not mandatory for approval of any future New Drug Application (NDA), Biologics License Application (BLA), or Abbreviated New Drug Application (ANDA). On the question of whether selection guarantees expedited product approval or inspection outcomes, FDA answers: "No. FDA PreCheck is intended to facilitate early alignment and regulatory predictability for facility development but does not guarantee expedited product reviews, approvals, or inspection outcomes."
2. A Pre-Operational Review (POR) site visit is not an inspection. FDA's structure page states that the POR may include a site visit and that "The site visit is not an inspection but note that all expectations outlined in the applicable Compliance Program and the Investigations Operations Manual (IOM) will be used to give FDA’s best assessment at the time as to whether the facility is ready for pre-submission meeting(s)." Because the visit is not an inspection, it is not the vehicle for Form FDA 483 observations, an Establishment Inspection Report (EIR), or an NAI/VAI/OAI classification, and it cannot satisfy a later product-specific pre-approval or pre-license inspection.
3. FDA does not approve or disapprove Drug Master Files. Under 21 CFR 314.420(a), FDA ordinarily neither independently reviews drug master files nor approves or disapproves them. The 1989 FDA Guideline for Drug Master Files states that a DMF is never approved or disapproved and is not a substitute for an IND, NDA, ANDA, or export application. PreCheck's structure page says FDA typically reviews DMFs upon reference, but intends to actively assess Type V DMFs submitted under the pilot and provide timely feedback. That is a pilot assessment practice, not a regulation rewriting 314.420, and not a facility license.
4. Compliance Program 7346.832 was revised the same day PreCheck participants were named. On June 29, 2026—the same calendar day FDA announced its initial seven PreCheck participants—CDER and the Office of Inspections and Investigations (OII) issued a revision to Compliance Program 7346.832, Preapproval Inspections (implementation date August 10, 2026). The cover page says the revision strengthens the risk-based strategy for deciding whether a PAI is needed and for conducting inspections efficiently. OII is to use that program for PAIs of manufacturing facilities supporting pending drug applications. Biologics follow Compliance Program 7346.832M, Date of Issuance April 14, 2026, implementation May 14, 2026. PreCheck does not withdraw either program.
5. Quality agreements cannot delegate statutory CGMP responsibility. 21 CFR 211.22 requires a quality control unit with authority to approve or reject drug products, including products manufactured, processed, packed, or held under contract by another company. FDA's November 2016 guidance, Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry, states that quality agreements cannot be used to delegate statutory or regulatory responsibilities to comply with CGMP. A PreCheck seat does not change that rule.

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                      PRECHECK PHASE 1 VS. PAI COMPLIANCE PROGRAMS VS. TYPE II API DMF                  │
├──────────────────────┬──────────────────────────────┬──────────────────────────┬───────────────────────┤
│ Dimension            │ FDA PreCheck Phase 1         │ FDA Compliance Program   │ Type II API DMF       │
│                      │ (POR & Type V Facility DMF)  │ 7346.832 (Rev. 06/29/26) │ (21 CFR 314.420(a)(2))│
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Governing Authority  │ Voluntary FDA pilot; one     │ CP 7346.832 for OII/CDER │ 21 CFR 314.420; DMF   │
│                      │ response to EO 14293         │ PAI; 21 U.S.C. 374;      │ is not a substitute    │
│                      │                              │ 21 CFR 314.125(b)(1),    │ for an NDA or ANDA     │
│                      │                              │ (b)(12), (b)(13)         │                      │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Legal Document Type  │ Type V Reference DMF         │ Agency inspectional      │ Chemistry, Mfg, and   │
│                      │ (21 CFR 314.420(a)(5))       │ standard for pending apps│ Controls submission   │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Inspectional Status  │ POR site visit is explicitly │ Formal regulatory PAI;   │ N/A; inspected only   │
│                      │ NOT an inspection; no EIR    │ yields Form FDA 483, EIR,│ during PAI or CGMP    │
│                      │ or NAI/VAI classification    │ and formal classification│ surveillance audits   │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Timing of Review     │ Pre-operational; before      │ Triggered during pending │ Triggered upon filing │
│                      │ commercial filings submit    │ NDA, ANDA, or BLA clock  │ of application LOA    │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Facility Approval?   │ No; a DMF is never approved; │ No standalone plant      │ No; a DMF is never    │
│                      │ the plant is not licensed    │ license; PAI recommend-  │ approved or           │
│                      │ by the Type V file           │ ation supports or with-  │ disapproved           │
│                      │                              │ holds application        │                       │
│                      │                              │ approval                 │                       │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ CGMP Responsibility  │ Owner and contractor both    │ Applicant remains        │ Applicant remains     │
│                      │ remain accountable; a        │ accountable; inspection  │ accountable for the   │
│                      │ quality agreement cannot     │ does not transfer CGMP   │ referenced API file    │
│                      │ delegate CGMP                │                          │                       │
└──────────────────────┴──────────────────────────────┴──────────────────────────┴───────────────────────┘

CMC teams evaluating new manufacturing facilities must distinguish between early agency technical dialogue and binding pre-approval inspection mandates. Outsourcing and regulatory leads should structure their RFQs and quality agreements around the exact operational boundaries of the PreCheck pilot.

---

What did FDA actually select on June 29 2026, and which facilities are ineligible for PreCheck?

The FDA PreCheck Pilot Program was established in response to Executive Order 14293, Regulatory Relief to Promote Domestic Production of Critical Medicines (signed May 5, 2025). The executive order directed federal agencies to reduce regulatory burdens that disincentivize domestic manufacturing, expand early engagement mechanisms before new facilities become operational, and refine risk-based inspection frameworks.

FDA formally launched PreCheck on February 1, 2026, creating an initial application window that closed on March 1, 2026. The agency received over 80 requests to participate from across the biopharmaceutical and manufacturing sectors. On June 29, 2026, FDA announced that it had selected an initial cohort of seven companies. On its July 21, 2026 domestic manufacturing hub (FDA Actions to Support and Strengthen Domestic Drug Manufacturing), the agency formally listed the seven participants:

• Eli Lilly and Company
• Regeneron Pharmaceuticals
• Amneal Pharmaceuticals
• Cellares
• Fujifilm Biotechnologies
• Kriya Therapeutics
• Kyowa Kirin

This participant list spans innovator pharmaceutical companies, generic drug manufacturers, and specialized CDMOs focused on cell therapy automated platforms, biologics drug substance, and advanced therapies. However, biopharma procurement and CMC teams must understand what this selection represents: it is an administrative eligibility list for a pilot study, not an agency endorsement, ranking, or compliance certification. Selection into the cohort does not imply that non-selected CDMOs operate deficient facilities, nor does it certify that the selected facilities are in CGMP compliance prior to commercial operation.

Furthermore, FDA established stringent eligibility boundaries that disqualify many common biopharma capital build-outs:

1. New Facilities Only; Expansions Are Ineligible: PreCheck eligibility is limited to a new manufacturing facility located in the United States or its insular areas. FDA's eligibility criteria state that the facility cannot be an existing facility or an extension of an existing facility. Adding a fill-finish suite or lyophilization bay to an established campus is therefore outside the published pilot, regardless of the line's sophistication. That is a program boundary, not a statute.
2. One Request Per Company: Applicants were permitted to submit only one request, covering a single facility.
3. Commitment to Near-Term Regulatory Submissions: Participants were required to commit to submitting an original NDA, ANDA, or BLA, or a post-approval supplement for drug substance (DS) or finished drug product (DP/FDF), or a Type II DMF for small-molecule active pharmaceutical ingredients (APIs).
4. Three-Year Domestic Manufacturing Obligation: Participants had to provide an express commitment to manufacture products in the assessed facility for at least 3 years following FDA approval of the products produced there during pilot participation. This criterion prevents companies from leveraging PreCheck resources for a rapid clinical validation run before mothballing or divesting the facility.
5. Exclusion of Distributed and Point-of-Care Systems: Distributed manufacturing (DM) platforms and Point-of-Care (POC) modular systems are formally excluded from the scope of PreCheck.
6. CDMO Information-Sharing Requirement: When CDMOs applied for PreCheck, FDA required documented agreements with experienced commercial sponsors and an explicit willingness to share critical facility design, qualification, and PreCheck meeting outcomes with proposed partner sponsors.

For sponsors evaluating CDMO partners, these boundaries are an RFQ filter. A claim that an existing-campus expansion is PreCheck-eligible contradicts the published eligibility page. A CDMO that will not share PreCheck facility information with a proposed partner sponsor is also out of step with the selection criterion that required a documented willingness to share that information. Put the sharing duty in the quality agreement rather than treating a cohort seat as proof of access.

---

Does a PreCheck Type V facility DMF, or a POR site visit, replace Compliance Program 7346.832 issued the same day or 7346.832M?

The most dangerous assumption an outsourcing team can make is that participation in PreCheck Phase 1 eliminates the need for an on-site Pre-Approval Inspection (PAI) or Pre-License Inspection (PLI).

Phase 1 of PreCheck centers on a Pre-Operational Review (POR) and a Type V facility Drug Master File. FDA's structure page describes POR as early engagement on facility design and construction, equipment design and qualification, and Pharmaceutical Quality System (PQS) design. The Type V DMF is the repository for facility-related information reviewed during POR. FDA has said it will provide further information on Type V content and procedures for the pilot; that table of contents is not posted yet. The POR may include a site visit.

FDA's structure page is explicit about the visit's legal status:

"The site visit is not an inspection but note that all expectations outlined in the applicable Compliance Program and the Investigations Operations Manual (IOM) will be used to give FDA’s best assessment at the time as to whether the facility is ready for pre-submission meeting(s)."

This distinction is the RFQ trap:

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                              PRE-OPERATIONAL REVIEW VS. PRE-APPROVAL INSPECTION                        │
├───────────────────────────────┬──────────────────────────────────┬─────────────────────────────────────┤
│ Procedural Step               │ PreCheck Pre-Operational Review  │ Statutory Pre-Approval Inspection   │
│                               │ (POR Site Visit)                 │ (Compliance Program 7346.832)       │
├───────────────────────────────┼──────────────────────────────────┼─────────────────────────────────────┤
│ Authority                     │ Voluntary FDA pilot            │ 21 U.S.C. 374 inspection      │
│                               │ (Phase 1 Facility Readiness)   │ authority; 21 CFR 314.125(b)  │
│                               │                                │ (1), (b)(12), (b)(13)         │
├───────────────────────────────┼──────────────────────────────────┼─────────────────────────────────────┤
│ Primary Purpose               │ Formative assessment of plant    │ Application-linked evaluation │
│                               │ design, equipment, and PQS       │ of manufacturing, CGMP, and  │
│                               │ readiness                        │ submitted data                │
├───────────────────────────────┼──────────────────────────────────┼─────────────────────────────────────┤
│ Document Issued at Exit       │ Meeting minutes and site visit   │ Form FDA 483 if observations  │
│                               │ memorandum, per FDA structure    │ exist                         │
│                               │ page                             │                               │
├───────────────────────────────┼──────────────────────────────────┼─────────────────────────────────────┤
│ Final Regulatory Deliverable  │ Feedback to the DMF holder;      │ Establishment Inspection      │
│                               │ not a public EIR                 │ Report (EIR) and NAI, VAI, or │
│                               │                                  │ OAI classification            │
├───────────────────────────────┼──────────────────────────────────┼─────────────────────────────────────┤
│ Application Action Impact     │ Informs Phase 2; does not        │ Supports or withholds         │
│                               │ authorize commercial release     │ application approval from a   │
│                               │                                  │ facility/CGMP perspective     │
└───────────────────────────────┴──────────────────────────────────┴─────────────────────────────────────┘

A POR site visit is documented with meeting minutes and a site visit memorandum. FDA's structure page also says participants may receive a post-site visit meeting to discuss findings. Because the visit is not an inspection, it is not a Form FDA 483 closeout and not a public EIR. It also cannot audit commercial batch records or process-performance-qualification packages that do not yet exist.

The same-day policy split matters. On June 29, 2026—the calendar day FDA announced the seven PreCheck participants—the agency issued revised Compliance Program 7346.832, Preapproval Inspections, with an implementation date of August 10, 2026 (56 pages). That revision superseded the September 16, 2022 issuance (implementation October 17, 2022). The cover page states the purpose of the rewrite: strengthen the risk-based strategy to make a prompt decision on the need for inspections and to promote efficient conduct of those inspections.

Part II of the 2026 program distinguishes two steps. A preapproval facility evaluation uses inspection history, compliance status, the drug being manufactured, and other application information to decide whether a PAI is needed before the application can be approved from a quality perspective. A preapproval inspection, if conducted, evaluates manufacturing processes, control strategy, CGMP, and whether data submitted in the application are accurate and complete. FDA may also use alternative tools, including remote regulatory assessments, when appropriate. A decision not to inspect a PreCheck facility would be an OPMA/OII outcome under CP 7346.832, not a PreCheck waiver, and must not be promised in an RFQ.

When a PAI is conducted, the June 29, 2026 program lists four primary inspectional objectives—not the three-objective summary still common in older recaps:

1. Readiness for Commercial Manufacturing: Whether the establishment has a quality system designed to achieve sufficient control over the facility and commercial manufacturing operations.
2. Conformance to Application: Whether commercial manufacturing and controls match the commitments in the pending application.
3. Data Integrity Audit: Whether data submitted in the application are authentic, accurate, and complete.
4. Commitment to Quality in Pharmaceutical Development: Whether the pharmaceutical development program is supported, defined, managed, and continuously assessed, including its use in supporting continual improvement of the pharmaceutical quality system. The 2026 program says this objective is covered on the initial PAI and periodically on later PAIs based on risk.

The inspection lead determines coverage depth. The program does not say every PAI must receive the same exhaustive on-site package. Do not treat those objective titles as an inspection-coaching checklist.

For biological drug substances and products, CDER uses Compliance Program 7346.832M, Date of Issuance April 14, 2026, implementation May 14, 2026 (Prelicense and Preapproval Inspections of CDER-Regulated Biological Product Manufacturers; 83 pages). As mapped in our analysis of PAI readiness for a launch-critical facility and our comparative review of Annex 1 CCS versus FDA 2004 aseptic RFQ, biological pre-license inspections still require product-specific auditing that a pre-operational visit cannot complete.

PreCheck Phase 1 does not withdraw CP 7346.832 or CP 7346.832M. Phase 2 is designed to support earlier inspection determinations inside the review cycle. That is an efficiency aim, not a statutory waiver. Treating a POR visit as a PAI waiver exposes the sponsor to CMC-only complete response letters if OPMA later requests an inspection the quality agreement never planned for.

---

How should a sponsor or CDMO RFQ split Type V facility information, Type II API information, and quality-agreement CGMP duties under 21 CFR 314.420?

To eliminate regulatory ambiguity, sponsors issuing an RFQ or drafting commercial master services and quality agreements must rigorously partition manufacturing data across three distinct administrative vehicles: Type V facility DMFs, Type II active ingredient DMFs, and the commercial Quality Agreement.

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                        REGULATORY ALLOCATION OF OUTSOURCED MANUFACTURING RESPONSIBILITIES              │
├──────────────────────┬──────────────────────────────┬──────────────────────────┬───────────────────────┤
│ Information Domain   │ Type V Facility DMF          │ Type II API DMF          │ Commercial Quality    │
│                      │ (21 CFR 314.420(a)(5))       │ (21 CFR 314.420(a)(2))   │ Agreement (CGMP)      │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Facility Design &    │ Facility-related information │ Out of scope (reference  │ Ongoing maintenance,  │
│ Equipment / PQS      │ reviewed during POR; FDA     │ via LOA). Do not mix     │ change control, and   │
│                      │ has not posted a Type V TOC  │ API chemistry into Type V│ access for the owner  │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Synthesis, Route &   │ Out of scope; facility file  │ Drug substance CMC:      │ Batch release, COA    │
│ Process Controls     │ is not the API process       │ route, specs, impurities,│ verification, testing │
│                      │                              │ batch controls           │ protocols, deviations │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Agency Assessment    │ Actively assessed under      │ Typically reviewed when  │ Inspected if a PAI is │
│ Framework            │ PreCheck Phase 1; feedback   │ a referencing NDA/ANDA   │ conducted; the        │
│                      │ to the holder, not approval  │ is assessed              │ agreement cannot      │
│                      │                              │                          │ delegate CGMP         │
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Change Notification  │ Holder notifies authorized   │ Same 21 CFR 314.420(c)   │ Operational windows   │
│ Mandate              │ persons under 21 CFR         │ duty; notice should come │ so the owner can file │
│                      │ 314.420(c); no 30-day clock  │ well before the change   │ 314.70/Q12 supplements│
├──────────────────────┼──────────────────────────────┼──────────────────────────┼───────────────────────┤
│ Legal Ownership      │ Facility owner / CDMO        │ API manufacturer / CDMO  │ Jointly executed by   │
│                      │                              │                          │ Applicant & Contractor│
└──────────────────────┴──────────────────────────────┴──────────────────────────┴───────────────────────┘

1. Understanding the Role and History of the Type V Facility DMF

A Type V DMF is not a newly created statutory classification. Under 21 CFR 314.420(a)(5), Type V is designated for "FDA-accepted reference information." Historically, manufacturing site and facility information was submitted under Type I DMFs (Manufacturing Site, Facilities, Operating Procedures, and Personnel). However, Type I DMFs were discontinued by FDA decades ago. As codified in the Code of Federal Regulations, 21 CFR 314.420(a)(1) is reserved, and FDA's Types of Drug Master Files (DMFs) page (content current as of May 19, 2025) lists only Types II through V.

Under ordinary regulatory practice, 21 CFR 314.420(a)(5) requires a party to submit a formal Letter of Intent (LOI) to FDA before submitting a Type V file containing information not covered by Types II through IV. FDA ordinarily discourages Type V filings unless the agency has specifically requested the information or established a program to accept it.

The PreCheck Pilot Program uses Type V DMFs as the vehicle for facility-specific information:

• FDA's structure page describes the Type V DMF as a central repository for facility-related information reviewed during POR that can be referenced in later applications. FDA intends to provide further information on Type V content and procedures for the pilot; those instructions were not posted as of 2026-09-07.
• While FDA typically reviews DMFs only when referenced by a marketing application, the agency intends to actively assess Type V DMFs submitted under PreCheck and provide timely feedback to the facility holder.
• The legal limit: Active assessment inside a pilot does not approve the DMF. Under 21 CFR 314.420(a), FDA ordinarily neither independently reviews DMFs nor approves or disapproves them. The Type V file remains a confidential reference that can be incorporated into later NDAs, ANDAs, or BLAs through a Letter of Authorization (LOA).

2. The Type II API DMF Boundary

For small-molecule drug substance manufacturing, the Type V facility file must remain strictly separated from the Type II API DMF governed by 21 CFR 314.420(a)(2). As detailed in our guide to API DMF letter-of-authorization traps, a Type II DMF contains the proprietary chemistry, manufacturing, and controls information for the drug substance: reaction routes, critical process parameters, starting material qualifications, impurity profiles, analytical methods, and stability data.

PreCheck Phase 2 may include earlier Type II DMF feedback for new U.S. API manufacturers supporting NDAs or ANDAs only. FDA's structure page presents that as an earlier-review opportunity, not a substitute for application assessment and not immunity from deficiency letters or Complete Response Letters (CRLs).

Furthermore, sponsors sourcing APIs from overseas must evaluate whether domestic PreCheck facilities resolve broader geopolitical or regulatory vulnerabilities, such as compliance mandates under the BIOSECURE Act DMF strategy or changing international logistics modeled in the generic drug tariff onshoring timeline.

3. Quality Agreement Non-Delegation Mandates

Under U.S. law, contractual terms cannot override CGMP statutes. When a sponsor contracts with a PreCheck CDMO, the quality agreement still has to document who does what without pretending CGMP was transferred:

• Quality control unit duties (21 CFR 211.22): The regulation requires a quality control unit with authority to approve or reject drug products, including products manufactured, processed, packed, or held under contract by another company. FDA's November 2016 quality-agreements guidance states that "quality agreements cannot be used to delegate statutory or regulatory responsibilities to comply with CGMP" and that "No party to a quality agreement may delegate any of its responsibilities to comply with CGMP through the quality agreement or any other means." Both the owner and the contract facility remain responsible. A PreCheck seat does not shrink the owner's oversight, audit, or batch-disposition duties.
• PreCheck information-sharing: FDA's selection criteria for CDMOs included agreements with experienced sponsors and a documented willingness to share information with proposed partner sponsors about the proposed facility. Put access to Type V content, POR meeting minutes, the site-visit memorandum, and related correspondence in the quality agreement. Do not treat cohort membership as a substitute for that clause.
• Change notification (21 CFR 314.420(c)): The DMF holder must notify each authorized person in writing of additions, changes, or deletions. The 1989 DMF guidelines say that notice should be provided well before making the change so the applicant can amend or supplement affected filings. 314.420(c) does not specify a 30-day clock; set the operational window in the quality agreement and map it to 21 CFR 314.70 or ICH Q12 established conditions where a supplement is required.
• Audit rights and PAI logistics: As highlighted in our review of CDMO quality-agreement red flags, the agreement still needs sponsor audit rights and a plan for a later PAI or alternative facility assessment under Compliance Program 7346.832. PreCheck does not write that plan.

---

What does FDA's own FAQ say PreCheck does not guarantee, and how does that differ from the AI Overview's "speed up the review" sentence?

A persistent challenge facing CMC leaders is the proliferation of automated search summaries and marketing recaps that collapse regulatory nuances into misleading catchphrases.

A 2026-09-07 DataForSEO organic brief for "FDA PreCheck program" showed an AI Overview assembled from FDA pages and trade recaps. That overview treated Phase 2 as helping speed the review of manufacturing details. Consultancy and logistics posts on the same results page used "game-changer" framing. Those sentences describe an aim. They are not a guarantee.

FDA's own FAQ, content current as of April 10, 2026, answers the guarantee question directly:

"No. FDA PreCheck is intended to facilitate early alignment and regulatory predictability for facility development but does not guarantee expedited product reviews, approvals, or inspection outcomes."

The structure page, also current as of April 10, 2026, states the remaining clock:

"The overall application review timeline is ultimately governed by several factors depending on the application type (e.g., user fee program, clinical, bioequivalence, and other non-facility-related CMC elements may control the review clock)."

┌────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│                          COMMERCIAL / AI CLAIMS VS. OFFICIAL FDA PRECHECK TEXT                         │
├──────────────────────────────────────┬─────────────────────────────────────────────────────────────────┤
│ Common Trade & AI Overview Claims    │ Official FDA Program Text (Content Current 04/10/2026)          │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ Selection speeds PDUFA clocks and    │ "FDA PreCheck ... does not guarantee expedited product          │
│ guarantees faster approvals.         │ reviews, approvals, or inspection outcomes."                    │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ Phase 2 shortens the overall         │ "The overall application review timeline is ultimately governed │
│ marketing-application review.        │ by several factors depending on the application type (e.g.,     │
│                                      │ user fee program, clinical, bioequivalence, and other           │
│                                      │ non-facility-related CMC elements may control the review        │
│                                      │ clock)."                                                        │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ PreCheck exempts the site from a     │ "The site visit is not an inspection." CP 7346.832, issued      │
│ product-specific PAI.                │ 06/29/2026 and implementing 08/10/2026, remains the PAI         │
│                                      │ playbook. A no-inspect decision would be a CP 7346.832 outcome. │
├──────────────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ An actively assessed Type V DMF      │ 21 CFR 314.420(a): FDA ordinarily neither independently         │
│ approves the manufacturing facility. │ reviews DMFs nor approves or disapproves them.                  │
└──────────────────────────────────────┴─────────────────────────────────────────────────────────────────┘

The contrast between marketing summaries and regulatory reality centers on three points:

1. User-fee clocks still control the application: PDUFA, BsUFA, and GDUFA goal dates are not rewritten by PreCheck Phase 1. If clinical, bioequivalence, labeling, or other non-facility CMC issues control the clock, facility engagement does not move the date. FDA's structure page says the overall timeline is ultimately governed by those factors.
2. Phase 2 is an efficiency aim, not a waiver: After Phase 1, FDA can reuse the facility knowledge base for later applications using the same site and may make earlier inspection determinations. Subsequent applications "may benefit" from that baseline. That is not a guaranteed shorter PDUFA clock and not a promise that no PAI will occur.
3. Do not confuse FDA PreCheck with payer tools: Biopharma market-access teams should not mix FDA PreCheck (the domestic manufacturing pilot) with UnitedHealthcare PreCheck MyScript (a pharmacy eligibility and prior-authorization tool). They share a name fragment and nothing else.

---

Which existing PharmaDossier pages own PAI readiness, Type II LOA traps, quality-agreement red flags, CNPV, generic-tariff onshoring, and fill-finish RFQ, and must not be rewritten here?

To maintain clear editorial boundaries across the PharmaDossier platform, this article focuses strictly on the PreCheck Type V facility DMF and Pre-Operational Review framework. Readers seeking comprehensive operational guidance on adjacent manufacturing, access, and regulatory disciplines should consult our dedicated reference assets:

• Product-Specific PAI / PLI Execution: For the operational mechanics of surviving a statutory inspection under Compliance Program 7346.832, 60-day facility notification windows, and commercial batch record readiness, see PAI readiness for a launch-critical facility.
• Type II API DMF Management: For detailed analyses of GDUFA completeness assessments, Letters of Authorization (LOAs), and mandatory 21 CFR 314.420(c) customer change-notification traps for active substance suppliers, see API DMF letter-of-authorization traps.
• CDMO Contractual Governance: For a breakdown of 483 inspection observations targeting vague quality agreements, unresolved OOS investigations, and lack of sponsor change control, see CDMO quality-agreement red flags.
• Domestic Manufacturing Incentives: To evaluate federal incentive programs that compress marketing review timelines rather than facility design audits, see our analysis of the Commissioner's National Priority Voucher pilot.
• Trade Policy and Macro Supply Chain Economics: For economic modeling of supply chain relocations, Section 232 duties, and finished dosage form sourcing, see the generic drug tariff onshoring timeline.
• Post-Approval Change Management: For regulatory protocols governing post-approval site transfers and established conditions under Module 3, see ICH Q12 established conditions.
• Sterile Fill-Finish Cleanroom Design: For dual-jurisdiction requirements governing EU GMP Annex 1 Contamination Control Strategies, PUPSIT requirements, and 2026 FDA warning letters rejecting claimed RABS lines, see Annex 1 CCS versus FDA 2004 aseptic RFQ.
• Geopolitical Sourcing and Entity Restrictions: For strategic navigation of API and CDMO sourcing risks under evolving federal legislation, see our guide to BIOSECURE Act DMF strategy.
• Commercial Failure Modes of CMC CRLs: For data on approval delays, PDUFA date misses, and market valuation impacts caused by facility-related Complete Response Letters, see CMC-only complete response letters.

---

Frequently Asked Questions (FAQ)

If a CDMO is one of the seven PreCheck participants, does that mean my product will skip a PAI?

No. Selection into the PreCheck Pilot Program is not a waiver of a product-specific inspection. OPMA may use Phase 1 information in its risk-based decision on whether a PAI is needed and how to scope it. That decision sits under Compliance Program 7346.832 (issued June 29, 2026; implemented August 10, 2026) for drugs and Compliance Program 7346.832M (issued April 14, 2026; implemented May 14, 2026) for CDER-regulated biologics. FDA's FAQ states that selection does not guarantee expedited inspection outcomes.

Is a Type V facility DMF approved when FDA actively assesses it during PreCheck?

No. Under 21 CFR 314.420(a) and FDA's 1989 DMF guideline, a DMF is never approved or disapproved. Active assessment under PreCheck Phase 1 is a pilot practice that provides early feedback on facility information to the DMF holder. The Type V file remains a confidential reference; it is not a marketing authorization and not a facility license.

Can I use PreCheck for an expansion of an existing US plant or for a distributed-manufacturing network?

No. FDA's eligibility criteria limit PreCheck to a new manufacturing facility in the United States or its insular areas that is not an existing facility and not an extension of an existing facility. Distributed manufacturing and point-of-care systems are out of scope. Expansions follow ordinary application and post-approval change pathways.

Did FDA replace the 2022 pre-approval inspection compliance program when it launched PreCheck?

The 2022 program was replaced by a later compliance-program revision, not by PreCheck. On June 29, 2026—the same day FDA named the seven PreCheck participants—CDER and OII issued revised Compliance Program 7346.832, Preapproval Inspections, implementation date August 10, 2026 (56 pages). That revision superseded the September 16, 2022 issuance (implementation October 17, 2022), which still ranked first in a 2026-09-07 organic search for the PAI compliance program. The 2026 program is the in-effect PAI playbook; PreCheck did not enact it and does not withdraw it.

---

Sources

1. U.S. Food and Drug Administration (FDA). FDA PreCheck Pilot Program. Program page. Content current as of April 10, 2026. Available at: https://www.fda.gov/industry/fda-precheck-pilot-program
2. U.S. Food and Drug Administration (FDA). FDA PreCheck Pilot Program Structure. Content current as of April 10, 2026. Available at: https://www.fda.gov/industry/fda-precheck-pilot-program/fda-precheck-pilot-program-structure
3. U.S. Food and Drug Administration (FDA). FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing. Press Announcement. Content current as of June 29, 2026. Available at: https://www.fda.gov/news-events/press-announcements/fda-selects-seven-participants-precheck-pilot-program-advance-us-drug-manufacturing
4. U.S. Food and Drug Administration (FDA). FDA Actions to Support and Strengthen Domestic Drug Manufacturing. Content current as of July 21, 2026. Available at: https://www.fda.gov/industry/fda-actions-support-and-strengthen-domestic-drug-manufacturing
5. U.S. Food and Drug Administration (FDA) CDER & OII. Compliance Program Guidance Manual 7346.832: Preapproval Inspections. Date of Issuance: June 29, 2026; Implementation Date: August 10, 2026. 56 pages. Available at: https://www.fda.gov/media/193382/download
6. U.S. Food and Drug Administration (FDA) CDER & OII. Compliance Program Guidance Manual 7346.832: Preapproval Inspections (Historical 2022 Version). Date of Issuance: September 16, 2022; Implementation Date: October 17, 2022. 58 pages. Available at: https://www.fda.gov/media/121512/download
7. U.S. Food and Drug Administration (FDA) CDER. Compliance Program Guidance Manual 7346.832M: Prelicense and Preapproval Inspections of CDER-Regulated Biological Product Manufacturers. Date of Issuance: April 14, 2026; Implementation Date: May 14, 2026. 83 pages. Available at: https://www.fda.gov/media/191983/download
8. U.S. National Archives and Records Administration (NARA). 21 CFR 314.420: Drug master files. Electronic Code of Federal Regulations (eCFR). Title 21 current as of September 3, 2026 (Title 21 last amended August 31, 2026); § 314.420 last amended 69 FR 13473 (March 23, 2004). Available at: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-G/section-314.420
9. U.S. Food and Drug Administration (FDA). Types of Drug Master Files (DMFs). Regulatory Overview. Content current as of May 19, 2025. Available at: https://www.fda.gov/drugs/drug-master-files-dmfs/types-drug-master-files-dmfs
10. U.S. Food and Drug Administration (FDA) CDER. Guideline for Drug Master Files. Technical Guidance for Industry. September 1989; Content current as of November 16, 2017. Available at: https://www.fda.gov/drugs/guidances-drugs/drug-master-files-guidelines
11. U.S. Food and Drug Administration (FDA). Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry. Final Guidance. Docket No. FDA-2013-D-0558. November 2016. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry
12. Executive Office of the President of the United States. Executive Order 14293: Regulatory Relief to Promote Domestic Production of Critical Medicines. Signed May 5, 2025; 90 FR 19615 (May 8, 2025). Available at: https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/
13. U.S. National Archives and Records Administration (NARA). 21 CFR 211.22: Responsibilities of quality control unit. eCFR Title 21 current as of September 3, 2026. Available at: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-B/section-211.22
14. U.S. National Archives and Records Administration (NARA). 21 CFR 314.125: Refusal to approve an NDA. eCFR Title 21 current as of September 3, 2026. Available at: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.125